Johns Hopkins University

Gilead Sciences, Inc.

Donald S Coffey

Robert H Getzenberg

Alan W Partin

Brian James Hicke

Shawn E Lupold

Yun Lin

Methods are provided for generating nucleic acid ligands of Prostate Specific Membrane Antigen (PSMA). The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to PSMA, and methods and compositions for the treatment and diagnosis of disease using the nucleic acid ligands.

Nucleic acid ligands to the prostate specific membrane antigen

Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.

Nuclear matrix proteins

Antibodies directed to nuclear matrix proteins (NMP) are provided. Such antibodies are useful markers in diagnosing and monitoring the stage of malignancy of a cell.

Antibodies to nuclear matrix proteins

Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.

Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. Also provided is an in vitro method for detecting prostate cancer in a sample employing a reagent that reacts with the NMP designated PC-1 (prostate cancer-1).

Growing community of inventors

Lutherville, MD, United States of America

Donald S Coffey